Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2010

View Archived Issues

Anvyl claims new allosteric modulators of nicotinic acetylcholine receptor alpha7

New antimalarial agents presented by 4SC

Czech scientists disclose new cell division protein kinase inhibitors

RaQualia discovers new CB2 receptor agonists

Roche identifies new inhibitors of GlyT-1

Crystal Biopharmaceutical describes new HDAC inhibitors

Abbott begins ABT-267 trial in healthy volunteers and patients with hepatitis C

Xenon Pharma begins phase II XEN-402 trial in postherpetic neuralgia

GSK describes mechanism of new antibacterial agent GSK-299423

Urocortin-2 has long-term beneficial effects in model of myocardial infarction

Add-on vandetanib to docetaxel improves progression-free survival in NSCLC

Combination of three transcription factors reprograms fibroblasts into cardiomyocytes

FDA grants NX-001 orphan drug status for prevention of delayed kidney graft function

Biogen Idec and Knopp Neurosciences collaborate on dexpramipexole for ALS

Repros seeks meeting with FDA to discuss phase III Androxal protocol

Intellect Neurosciences locks database for phase Ib OX-1 trial

FDA grants Urigen Pharmaceuticals type C meeting for URG-101

CSL Behring receives FDA approval to extend shelf life of Hizentra

Quark Pharma and Novartis enter into licensing option agreement for QPI-1002

Shire withdraws NDA for ProAmatine

BioMarin acquires ZyStor Therapeutics and its lead product ZC-701

Chugai provides update on R&D developments

Clavis begins enrollment in phase III trial of elacytarabine in late-stage AML

FDA grants priority review to ipilimumab in previously treated advanced melanoma

FDA grants orphan status to lorvotuzumab mertansine for small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...